Ferrer offers $122M biobucks for ex-US license to Verge ALS drug
More than 350 Latin American doctors participate in the second Ferrer Summit in the region
More than 1,200 Ferrer volunteers join in a global commitment to social justice during our Days for Good
The World Health Organization includes the cardiovascular polypill developed by the CNIC and Ferrer in the list of essential medicines
We allocate more than 40% of our profits to social and environmental projects for the third consecutive year
We extend our clinical trial in amyotrophic lateral sclerosis
Ferrer4Future launches an open innovation challenge to promote digital solutions for ALS
We’ve been awarded EcoVadis GOLD Rating!
Ferrer acquires worldwide rights to ASN90, an O-GlcNAcase inhibitor to treat Progressive Supranuclear Palsy (PSP)
The Bellvitge University Hospital and Ferrer collaborate to promote innovation in the field of health